Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea
Variability of Fibrinolytic Markers and Endothelial Function in Obstructive Sleep Apnea
Obstructive sleep apnea is a condition in which people have decreased breathing during their sleep. Untreated sleep apnea has been linked to increased risk for cardiovascular diseases.
This research study is looking at blood clotting factors and blood vessel function in health volunteers and patients with newly diagnosed or untreated obstructive sleep apnea to better understand the underlying mechanisms for increased cardiovascular risk.
調査の概要
状態
条件
詳細な説明
Cardiovascular disease (CVD), which includes strokes, has been the number one killer in the United States.Each year about 700,000 people experience a new or recurrent stroke, which translates into about one stroke every 45 seconds. Apart from traditional risk factors for stroke such as hypertension, smoking and atrial fibrillation, obstructive sleep apnea is now being increasingly recognized as another important treatable risk factor.
The majority of strokes and myocardial infarctions are due to atherothrombotic events. Impaired fibrinolytic activity increases the propensity for thromboembolic events. Many different candidate molecules have been studied as the cause of a hypercoagulable state. Plasminogen Activator Inhibitor-1 (PAI-1) is the major physiologic inhibitor of the body's fibrinolytic system including the principal serine protease tissue-type plasminogen activator (t-PA). It is therefore poised to be a pivotal regulator of the fibrinolytic system.Recent studies have shown that PAI-1 levels are elevated in patients with obstructive sleep apnea (OSA) and that PAI-1 levels correlate with severity of OSA.
The purpose of this pilot study is twofold:
- To characterize changes in the blood levels of plasminogen activator inhibitor-1 (PAI-1) and tissue type plasminogen activator ( t-PA) across the 24 hour cycle in patients with obstructive sleep apnea, as compared to normal controls, and to further identify the pattern of changes with varying severity of obstructive sleep apnea, and
- To study endothelial function in patients with obstructive sleep apnea, as compared to normal controls.
Data gathered from this pilot study will be used to initiate a more comprehensive prospective study exploring the link between OSA, endothelial function, the fibrinolytic system and cardiovascular events. This area can be further explored by prospectively following patients to assess for a reduction in such events with treatment of OSA.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University Medical Center,Department of Neurology
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age 18 years or older.
- Subjects are able and willing to provide informed consent.
- Subjects are willing to cooperate with polysomnography and have serial blood draws over a 24-hour period.
- Evidence for OSA (AHI>5 events/hour) without treatment or suspected OSA based on symptoms in the patient group.
- Body mass index of 25-45
Exclusion Criteria:
- History of myocardial infarction, stroke or transient ischemic attack (TIA) or peripheral vascular disease.
- History of chronic diseases such as diabetes mellitus, uncontrolled hypertension (SBP >160, DBP > 120), renal failure on dialysis, cancer, autoimmune or liver disease.
- A significant history of medical or psychiatric disease that may impair participation in the trial.
- Evidence of medical instability (cardiac arrhythmias, congestive heart failure, pulmonary disease) that require an expedited evaluation and treatment of the OSA.
- History of alcohol, or drug abuse during the one-year-period prior to trial participation.
- Current use of tobacco products.
- Current treatment with angiotensin converting enzyme-inhibitors and or chronic use of non-steroidal anti-inflammatory agents.
- Another primary sleep disorder that requires intervention with medications or cause disrupted sleep.
- Patients with unusual sleep or wake habits, including shift work.
- Transmeridian travel in the previous 3 months.
- Patients with OSA who have already received treatment with CPAP, surgery or oral appliance.
- Pregnancy; as hormonal changes affect sleep disordered breathing.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Healthy controls
18 years or older with body mass index between 25-45
|
Obstructive Sleep Apnea Group
Age 18 years or older with body mass index between 25 and 45
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Comparison of Levels of Mean PAI-1 Activity in Patients With Obstructive Sleep Apnea and Controls.
時間枠:at the initial visit
|
at the initial visit
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Comparison of Endothelial (Blood Vessel) Wall Diameter in Patients With Obstructive Sleep Apnea Versus Controls.
時間枠:at initial visit
|
at initial visit
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Kanika Bagai, M.D、Vanderbilt University Medical Center, Nashville, TN
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
閉塞性睡眠時無呼吸の臨床試験
-
University Hospital, Bonnわからない合併症 | 睡眠時無呼吸 (Apnea Hypopnea Index > 5/h として定義) | 頭蓋内動脈瘤のサイズ | 血圧の薬 | 合併症(くも膜下出血)ドイツ